Amycretin Phase 2 Results: How a Dual-Hormone Oral Pill Achieved 25% Weight Loss | iMedic
Quick Facts
How Does Amycretin Target Two Hormonal Pathways in One Pill?
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells following meals. It acts on the area postrema and nucleus tractus solitarius in the brainstem to promote satiety, slow gastric emptying, and suppress postprandial glucagon secretion. GLP-1 (glucagon-like peptide-1), released from intestinal L-cells, similarly reduces appetite through central nervous system signaling while also enhancing glucose-dependent insulin release. By engaging both receptor systems, amycretin creates overlapping but non-identical suppression of caloric intake — a strategy that may explain why its weight loss outcomes exceed those of agents targeting GLP-1 alone.
Designing an oral molecule that effectively activates peptide hormone receptors presented considerable pharmaceutical challenges. Peptides are typically degraded in the gastrointestinal tract before reaching systemic circulation, which is why most GLP-1 receptor agonists require subcutaneous injection. Oral semaglutide (Rybelsus) addressed this partly through a permeation enhancer (SNAC), but achieved more modest weight loss compared to its injectable counterpart. Amycretin's formulation strategy, while not fully disclosed, appears to achieve sufficient oral bioavailability to drive weight reductions comparable to injected therapies — a technical achievement that has drawn attention from both endocrinologists and pharmaceutical scientists.
What Does the Phase 2 Dose-Response Curve Tell Us About Optimal Dosing?
In the Phase 2 program, multiple dose cohorts were evaluated to map amycretin's efficacy and tolerability profile. The lowest doses produced weight reductions in the range of 10–15%, which already matches or exceeds approved oral anti-obesity medications such as orlistat (typically 5–8%) and naltrexone-bupropion (approximately 5–9%). At the highest tested doses, weight loss reached approximately 25%, demonstrating that the dose-response relationship had not yet plateaued — an observation that suggests even greater efficacy might be achievable with further dose optimization, though tolerability constraints must be carefully balanced.
Gastrointestinal side effects, including nausea, vomiting, and diarrhea, are characteristic of incretin-based therapies and were observed across dose groups. However, the structured dose-escalation protocol — where patients started at lower doses and titrated upward over weeks — appeared to reduce the frequency and severity of these events compared to flat-dose initiation. The dropout rate due to adverse effects remained manageable even at higher doses, which is an encouraging signal for Phase 3 feasibility. Novo Nordisk selected specific doses from this curve to advance into pivotal efficacy trials, balancing the goal of maximal weight reduction against real-world tolerability.
How Do Amycretin's Phase 2 Results Compare to Other Oral Obesity Treatments in Development?
The oral anti-obesity pipeline has expanded rapidly, with several pharmaceutical companies pursuing non-injectable approaches. Pfizer's oral GLP-1 receptor agonist danuglipron showed modest weight loss in early trials before the company shifted focus to a next-generation formulation. Viking Therapeutics reported that its oral dual GIP/GLP-1 agonist VK2735 produced up to approximately 8% weight reduction over 28 days in Phase 1 data. Structure Therapeutics' oral GLP-1 agonist GSBR-1290 has also entered clinical testing. Against this landscape, amycretin's approximately 25% Phase 2 result represents a substantial efficacy advantage, though cross-trial comparisons carry inherent limitations due to differences in study populations, treatment duration, and dose-escalation schedules.
The competitive significance extends beyond efficacy numbers. If confirmed in Phase 3, amycretin could narrow the gap between oral and injectable obesity therapies to the point where the choice becomes one of patient preference and cost rather than clinical necessity. Currently, injectable semaglutide 2.4 mg (Wegovy) produces approximately 15–17% weight loss, and tirzepatide (Zepbound) achieves up to 22–26% in clinical trials. An oral tablet approaching these figures would represent a genuine inflection point in obesity medicine, potentially shifting the standard of care toward pill-based first-line therapy for a condition affecting over one billion people globally according to 2024 WHO estimates.
Frequently Asked Questions
Oral peptide-based drugs require fasting conditions to maximize absorption. Food in the stomach alters gastric pH, increases enzymatic degradation, and dilutes the drug, all of which can reduce bioavailability. Patients are typically instructed to take amycretin with a small amount of water at least 30 minutes before eating, similar to the dosing instructions for oral semaglutide (Rybelsus). This fasting requirement ensures consistent drug absorption across doses.
The most commonly reported side effects included nausea, vomiting, diarrhea, and decreased appetite — consistent with the known effects of GLP-1 and amylin receptor activation on the gastrointestinal system. These effects were generally mild to moderate and tended to diminish over time, particularly when patients followed the gradual dose-escalation protocol. Severe gastrointestinal events leading to treatment discontinuation occurred but were relatively infrequent compared to flat-dose initiation approaches.
While amycretin's approximately 25% weight loss approaches the lower range of surgical outcomes, bariatric surgery typically produces 25–35% total body weight reduction with durable results over many years. Whether pharmacotherapy can match surgery's long-term durability remains unknown, since drug-induced weight loss often reverses upon discontinuation. Amycretin may serve as an alternative for patients who are not surgical candidates or who prefer non-invasive treatment, but dedicated long-term comparison studies would be needed before it could be positioned as a surgical replacement.
References
- Novo Nordisk A/S. Novo Nordisk Capital Markets Day 2025: Pipeline Update on Oral Amycretin. 2025.
- World Health Organization. WHO Acceleration Plan to Stop Obesity. Geneva: WHO; 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.